2024-03-29T12:02:19Z
https://soar-ir.repo.nii.ac.jp/oai
oai:soar-ir.repo.nii.ac.jp:00008078
2022-12-14T04:00:49Z
882:883
Fetal Goitrous Hypothyroidism due to Maternal Thyroid Stimulation-Blocking Antibody: A Case Report
Ohira, Satoshi
Miyake, Masako
Kobara, Hisanori
Kikuchi, Norihiko
Osada, Ryosuke
Ashida, Takashi
Hirabayashi, Kanae
Nishio, Shin-ichi
Kanai, Makoto
Shiozawa, Tanri
Congenital hypothyroidism
Fetal goiter
Maternal hypothyroidism
Thyroid stimulation-blocking antibody
Transplacental passage
Most fetal goitrous hypothyroidisms are reportedly caused by the maternal use of an antithyroid drug or fetal dyshormonogenesis. However, fetal goitrous hypothyroidism due to the transplacental passage of maternal thyroid stimulation-blocking antibody (TSBAb) is extremely rare. A woman at 28 weeks of gestation was found to have a fetal goiter by ultrasonography. Because the maternal serum showed hypothyroidism with an elevated titer of TSBAb, levothyroxine sodium was administered. The patient delivered a male infant, 3,412 g, with a goiter at term. Umbilical blood revealed primary hypothyroidism with increased TSBAb, and the infant was given levothyroxine sodium. After a month, neonatal thyroid function and TSBAb levels became normal. Attention should be paid to possible fetal hypothyroidism when a fetal goiter is observed to avoid impaired mental development of the neonate.
Article
FETAL DIAGNOSIS AND THERAPY. 28(4):220-224 (2010)
journal article
KARGER
2010
application/pdf
FETAL DIAGNOSIS AND THERAPY
4
28
220
224
1015-3837
AA10799012
https://soar-ir.repo.nii.ac.jp/record/8078/files/Fetal_Goitrous_Hypothyroidism_Maternal_Thyroid_Stimulation-Blocking_Antibody.pdf
eng
20881365
https://pubmed.ncbi.nlm.nih.gov/20881365
10.1159/000320098
https://doi.org/10.1159/000320098
Copyright© 2010 S. Karger AG, Basel